Voyager Therapeutics (VYGR) to Release Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR) will likely be releasing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $7.8580 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 20, 2025 at 4:00 PM ET.

Voyager Therapeutics Price Performance

VYGR stock opened at $4.23 on Monday. The firm has a market capitalization of $234.64 million, a P/E ratio of -2.29 and a beta of 0.95. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $7.44. The company’s 50 day simple moving average is $4.51 and its 200-day simple moving average is $3.71.

Analyst Ratings Changes

Several analysts recently issued reports on VYGR shares. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Monday, September 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush reduced their price target on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $12.96.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares in the company, valued at $591,926.52. This trade represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Voyager Therapeutics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after buying an additional 40,147 shares in the last quarter. Jane Street Group LLC grew its position in Voyager Therapeutics by 92.6% during the 2nd quarter. Jane Street Group LLC now owns 27,844 shares of the company’s stock worth $87,000 after acquiring an additional 13,389 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at $78,000. Invesco Ltd. increased its position in Voyager Therapeutics by 30.4% in the 2nd quarter. Invesco Ltd. now owns 63,298 shares of the company’s stock valued at $197,000 after acquiring an additional 14,758 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in Voyager Therapeutics by 118.5% in the 2nd quarter. Hsbc Holdings PLC now owns 148,377 shares of the company’s stock worth $440,000 after purchasing an additional 80,474 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.